Dylewski J, Clecner B, Dubois J, St-Pierre C, Murray G, Bouchard C, Phillips R
St. Mary's Hospital, Montreal, Quebec, Canada.
Antimicrob Agents Chemother. 1993 Jun;37(6):1373-4. doi: 10.1128/AAC.37.6.1373.
We performed a single blind controlled multicenter study in which we compared the efficacy and safety of 100 mg of doxycycline versus those of 1 g (3 x 10(6) IU) of spiramycin given orally twice daily for 14 days in the treatment of culture-positive Chlamydia trachomatis genitourinary tract infections. A total of 367 patients were enrolled in the study, and 364 patients were evaluable for safety and 265 patients were evaluable for efficacy. The cure rate between treatment groups was not statistically significant, being 98% (125 of 128 patients) in the spiramycin group and 100% (133 of 133 patients) in the doxycycline group. Female patients who received spiramycin were more likely to report dysethesias that resolved after the completion of therapy. The results of the study show that spiramycin is an effective drug for the treatment of C. trachomatis infection and warrants further assessment over a shorter treatment period (7 days) and during pregnancy.
我们进行了一项单盲对照多中心研究，比较了100毫克强力霉素与1克（3×10⁶国际单位）螺旋霉素的疗效和安全性，二者均每日口服两次，连续服用14天，用于治疗衣原体培养阳性的泌尿生殖道感染。共有367名患者参与该研究，其中364名患者可进行安全性评估，265名患者可进行疗效评估。治疗组之间的治愈率无统计学差异，螺旋霉素组的治愈率为98%（128例患者中的125例），强力霉素组为100%（133例患者中的133例）。接受螺旋霉素治疗的女性患者更有可能报告感觉异常，这些症状在治疗结束后消失。研究结果表明，螺旋霉素是治疗沙眼衣原体感染的有效药物，值得在更短的治疗期（7天）以及孕期进行进一步评估。
